All News
More on Methotrexate and ILD Risk
To assess the progression of the interstitial lung disease related to Methotrexate (MTX) exposure, and to evaluate the lung involvement in RA non-ILD patients with MTX exposure, a systematic review was performed to assess whether RA patients receiving methotrexate (MTX) are at greater risk f
IL-1 Inhibition in CPPD
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
Read Article
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE https://t.co/vjpvILrJOt https://t.co/HepyZrYW5L
Dr. John Cush RheumNow ( View Tweet)
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. https://t.co/WRXG91AqmJ https://t.co/hMgddPXhxG
Links:
Dr. John Cush RheumNow ( View Tweet)
Day 2 Recap: #ACR25 Highlights
Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap.
https://t.co/aBxLuDhIMC https://t.co/q75eHf45Gt
Dr. John Cush RheumNow ( View Tweet)
Putting Steroid Tapering into Practice in SLE
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25. https://t.co/TtDC1pnaJr
Dr. John Cush RheumNow ( View Tweet)
CAR-T Therapy: Where is it Heading?
Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.
https://t.co/bC8p1LnZMW https://t.co/KKn3jjsBW0
Dr. John Cush RheumNow ( View Tweet)
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI
AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. AS, in particular, poses a diagnostic challenge—its early imaging https://t.co/TH2YIiPPEq
Dr. John Cush RheumNow ( View Tweet)
Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1).
Dr. John Cush RheumNow ( View Tweet)
Sjögren's disease RCTs: Has the Long Drought Ended?
At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
https://t.co/nNNx5sXzCz https://t.co/r9VBgyYgOC
Dr. John Cush RheumNow ( View Tweet)
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use
Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
Dr. John Cush RheumNow ( View Tweet)
Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: https://t.co/oa2wxIRGZv https://t.co/wyZYdabM2G
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic use in 5008 IBD pts finds higher serious infxn (SIE) rates (vs, RA or PsO). In UC the SIE rate was 5.5/100PY w/ vedolizumab & 7/100PY w/ other biologics. In Crohns the SIE rate was 7.9/100PY w/ vedolizumab vs 6.5/100PY w/ other biologics (adj HR 1.15; 0.95–1.40) (P .16) https://t.co/R7YC220NnO
Dr. John Cush RheumNow ( View Tweet)
Genetic Risks and Severe Cutaneous Reactions to Allopurinol
A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
Dr. John Cush RheumNow ( View Tweet)
Swedish Birth Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, including preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx
Dr. John Cush RheumNow ( View Tweet)
NHANES study of 4,622 adults, including 296 w/ RA, shows volatile organic compounds (VOCs) & metabolites (mVOCs) exposures increases the risk of #RA (OR: 1.23 - 1.37), especially in females. https://t.co/pBNLTRkyLn https://t.co/L6nVbYlBhD
Dr. John Cush RheumNow ( View Tweet)
#ACR25 PsA Topic Panel
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now. https://t.co/PP0fkweXsZ
Dr. John Cush RheumNow ( View Tweet)
New Approaches to Therapy in PsA
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
https://t.co/9vHgQ6S2JD https://t.co/5mvX1rOrIP
Links:
Dr. John Cush RheumNow ( View Tweet)
Why I love the late breaking abstracts
https://t.co/jCSfNOoFeT https://t.co/uZWSm9SQAI
Dr. John Cush RheumNow ( View Tweet)
Tuesday Nite Rheumatology (on 11.11.25) https://t.co/xk8NOwLN7z
Links:
Dr. John Cush RheumNow ( View Tweet)
